Page last updated: 2024-11-13

ati 5923

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tecarfarin: a vitamin K epoxide reductase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54718618
CHEMBL ID2105664
SCHEMBL ID1647984
MeSH IDM0543826

Synonyms (34)

Synonym
D09676
867257-26-9
tecarfarin (usan/inn)
tecarfarin
benzoic acid, 4-((4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl)-, 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl ester
ati-5923
2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl 4-((4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl)benzoate
wn1479yt50 ,
unii-wn1479yt50
tecarfarin [usan:inn]
ati 5923
ati5923
CHEMBL2105664
1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2h-chromen-3-yl)methyl]benzoate
tecarfarin [inn]
tecarfarin [usan]
2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl 4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate
tecarfarin [who-dd]
SCHEMBL1647984
DTXSID90235788
AKOS030535872
DB12823
HY-14854
CS-0003597
(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
SB18978
ati-5923; ati 5923; ati5923
BCP31892
Q27292724
MS-28430
1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate
qflntqdovclqkw-uhfffaoysa-n
1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl4-((4-hydroxy-2-oxo-2h-chromen-3-yl)methyl)benzoate
benzoic acid, 4-[(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)methyl]-, 2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl?ester

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Tecarfarin was well tolerated without serious adverse events."( Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.
Chen, Z; Dai, X; Hu, W; Li, X; Wang, H; Wang, Z; Yu, X; Zhang, Y; Zhou, Q; Zhou, R, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" To evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety of tecarfarin, we performed single ascending dose (SAD) (n=66), multiple ascending dose (MAD) (n=43), and tecarfarin versus warfarin (n=28) studies in human volunteers."( Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
Albrecht, D; Canafax, DM; Combs, D; Druzgala, P; Ellis, D; Midei, MG; Milner, PG, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" They have a slow onset and offset of action, narrow therapeutic window, marked dose-response variability, and multiple food and drug interactions, and require frequent coagulation monitoring and dose adjustments."( Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Mangiafico, M; Mangiafico, RA, 2012
)
0.38
" Dosing of study drugs was managed by a centralised dose control centre, which had access to genotyping."( A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Albrecht, D; Canafax, DM; Ellis, D; Fordyce, CB; Garcia, D; Midei, MG; Milner, PG; Weitz, JI; Whitlock, RP, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's8 (80.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.44 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (50.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (40.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]